KRAS-EphA-2-CAR-DC
/ Chinese PLA General Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 25, 2025
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=9 | Active, not recruiting | Sponsor: Chinese PLA General Hospital | Recruiting ➔ Active, not recruiting | N=15 ➔ 9 | Trial primary completion date: Dec 2025 ➔ Jun 2026
Enrollment change • Enrollment closed • IO biomarker • Trial primary completion date • Solid Tumor • KRAS
February 16, 2024
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: Chinese PLA General Hospital | N=10 ➔ 15
Combination therapy • Enrollment change • IO biomarker • Metastases • Oncology • Solid Tumor • KRAS
February 08, 2023
Combination of CAR-DC Vaccine and Anti-PD-1 Antibody in Local Advanced/Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Chinese PLA General Hospital | N=20 ➔ 10
Combination therapy • Enrollment change • IO biomarker • Metastases • Oncology • Solid Tumor • IL10 • IL2 • IL6 • KRAS
November 30, 2022
Combination of CAR-DC Vaccine and PD-1 Antibody in Local Advanced/Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Chinese PLA General Hospital
Combination therapy • IO biomarker • New P1 trial • Oncology • Solid Tumor • IL10 • IL2 • IL6 • KRAS
1 to 4
Of
4
Go to page
1